These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 10852642)
21. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
22. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Adkins JC; Faulds D Drugs; 1997 Oct; 54(4):615-33. PubMed ID: 9339964 [TBL] [Abstract][Full Text] [Related]
24. Dyslipidaemia in type 2 diabetes mellitus: bad for the heart. Katsiki N; Tentolouris N; Mikhailidis DP Curr Opin Cardiol; 2017 Jul; 32(4):422-429. PubMed ID: 28362666 [TBL] [Abstract][Full Text] [Related]
25. High prevalence of dyslipidaemia despite adequate glycaemic control in patients with diabetes. Loh KC; Thai AC; Lui KF; Ng WY Ann Acad Med Singap; 1996 Mar; 25(2):228-32. PubMed ID: 8799011 [TBL] [Abstract][Full Text] [Related]
26. Lipids in type 2 diabetes. Laakso M Semin Vasc Med; 2002 Feb; 2(1):59-66. PubMed ID: 16222596 [TBL] [Abstract][Full Text] [Related]
27. Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia. Keating GM; Ormrod D Drugs; 2002; 62(13):1909-44. PubMed ID: 12215067 [TBL] [Abstract][Full Text] [Related]
28. Dyslipidemias in diabetic patients. Is standard cholesterol treatment appropriate? Gates G Postgrad Med; 1994 Feb; 95(2):69-70, 77-9, 83-4. PubMed ID: 8309864 [TBL] [Abstract][Full Text] [Related]
29. Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Farnier M Am J Cardiovasc Drugs; 2003; 3(3):169-78. PubMed ID: 14727929 [TBL] [Abstract][Full Text] [Related]
30. Treatment of dyslipoproteinaemia in diabetes mellitus. Dean JD; Durrington PN Diabet Med; 1996 Apr; 13(4):297-312. PubMed ID: 9162604 [TBL] [Abstract][Full Text] [Related]
31. Lipids and lipoproteins as risk factors for coronary heart disease in non-insulin-dependent diabetes mellitus. Laakso M Ann Med; 1996 Aug; 28(4):341-5. PubMed ID: 8862689 [TBL] [Abstract][Full Text] [Related]
32. Statin therapy for the treatment of diabetic dyslipidemia. Haffner SM Diabetes Metab Res Rev; 2003; 19(4):280-7. PubMed ID: 12879405 [TBL] [Abstract][Full Text] [Related]
33. Lipids and atherogenesis in diabetes mellitus. Betteridge DJ Atherosclerosis; 1996 Jul; 124 Suppl():S43-7. PubMed ID: 8831915 [TBL] [Abstract][Full Text] [Related]
34. Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus. Keating GM; Croom KF Drugs; 2007; 67(1):121-53. PubMed ID: 17209672 [TBL] [Abstract][Full Text] [Related]
35. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. Reiner Z Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901 [TBL] [Abstract][Full Text] [Related]
36. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. Castaño G; Fernández L; Mas R; Illnait J; Mesa M; Fernández JC Clin Drug Investig; 2003; 23(10):639-50. PubMed ID: 17535079 [TBL] [Abstract][Full Text] [Related]
37. Drug treatment of combined hyperlipidemia. Wierzbicki AS; Mikhailidis DP; Wray R Am J Cardiovasc Drugs; 2001; 1(5):327-36. PubMed ID: 14728015 [TBL] [Abstract][Full Text] [Related]
38. Plasma lipoprotein abnormalities in type 1 (insulin-dependent) diabetes mellitus. Dullaart RP Neth J Med; 1995 Jan; 46(1):44-54. PubMed ID: 7877714 [TBL] [Abstract][Full Text] [Related]